Ben Samelson-Jones: Long-Term Safety and Efficacy of AAV Gene Therapy Using FIX-Padua in Hemophilia B
Ben Samelson-Jones, Associate Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia and Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Sustained long term safety and efficacy (up to 6 years) with AAV gene therapy using FIX-Padua for hemophilia B.”
Title: Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B
Authors: Benjamin J Samelson-Jones, John EJ Rasko, Jonathan Ducore, Catherine McGuinn, Lindsey A. George, Sylvia von Mackensen, Gianluca Borgonuovo, Delphine Agathon, Lynne Smith, Lisa J Wilcox, Francesca Biondo, Frank Plonski
Read the Full Article on Blood Advances
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS